Introduction
Trifluridine/tipiracil (FTD/TPI) combined with bevacizumab has emerged as a significant treatment option for metastatic colorectal cancer (mCRC), especially in patients who have undergone prior chemotherapy. This combination leverages the independent mechanisms of action of FTD/TPI and bevacizumab, with preclinical evidence suggesting enhanced efficacy through increased FTD accumulation in tumor cell DNA.
Clinical Trials Overview
The pooled safety analysis draws on data from the SOLSTICE and SUNLIGHT phase 3 trials, which evaluated the efficacy and safety of FTD/TPI plus bevacizumab in previously untreated or refractory mCRC patients. These global, open-label, randomized trials included patients with unresectable adenocarcinoma of the colon or rectum, adequate organ function, and an estimated life expectancy of at least 12 weeks.
Safety Findings
The analysis revealed that treatment-emergent adverse events (TEAEs) were consistent with the known safety profiles of FTD/TPI and bevacizumab. The most common TEAEs included neutropenia, anemia, nausea, diarrhea, and fatigue. Notably, grade ≥3 TEAEs were more frequent in the SOLSTICE trial, likely due to the longer treatment duration and older patient population.
Management of Adverse Events
Effective management strategies, including dose modifications and the use of granulocyte colony-stimulating factor (G-CSF), were pivotal in mitigating hematologic TEAEs. The median time to onset of grade ≥3 hematologic TEAEs was similar across both trials, indicating that prior treatment did not predispose patients to earlier-onset neutropenia.
Conclusion
This pooled safety analysis reaffirms the manageable safety profile of FTD/TPI plus bevacizumab in mCRC treatment. The combination's tolerability across different lines of therapy, coupled with effective adverse event management strategies, underscores its potential as a viable treatment option for mCRC patients.
Data Availability and Ethics
Study-level clinical data are available upon reasonable request, and the trials were conducted in compliance with ethical standards, including the Declaration of Helsinki and Good Clinical Practice guidelines.
Acknowledgments
The research was supported by Servier International Research Institute and Taiho Oncology, Inc., with medical writing assistance provided by Envision Pharma Group.
